Recently it has been shown that KRT-232 inhibits tumor growth in BRAF WT melanoma PDXs, and KRT-232 in combination with BRAF or MEK inhibitors showed a synergistic effect in BRAF V600–mutant tumors46. This evidence concerns the gene BRAF and neoplasm.